Standout Papers
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial (2011)
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy (2005)
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial (2016)
Immediate Impact
3 by Nobel laureates 17 from Science/Nature 86 standout
Citing Papers
Wireless Technologies in Flexible and Wearable Sensing: From Materials Design, System Integration to Applications
2024 Standout
Deciphering breast cancer: from biology to the clinic
2023 Standout
Works of Paolo Morandi being referenced
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
2005 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Paolo Morandi | 1084 | 3165 | 409 | 2238 | 85 | 5.7k | |
| Richard Greiner | 605 | 1612 | 256 | 974 | 129 | 5.7k | |
| Takeshi Kishida | 195 | 776 | 53 | 1513 | 140 | 4.5k | |
| Binbin Wang | 139 | 2001 | 39 | 1753 | 33 | 6.5k | |
| Andreas Makris | 154 | 2827 | 62 | 2956 | 140 | 6.2k | |
| Gustavo Ayala | 89 | 1873 | 19 | 1056 | 113 | 6.6k | |
| Andrés Poveda | 66 | 2304 | 64 | 583 | 154 | 5.6k | |
| Muhammed Murtaza | 31 | 2125 | 17 | 4098 | 57 | 5.4k | |
| Zhenwei Peng | 11 | 891 | 77 | 689 | 180 | 5.2k | |
| Michele Magni | 19 | 1260 | 3 | 378 | 96 | 5.1k | |
| Pedro L. Fernández | 5 | 2109 | 5 | 1525 | 182 | 6.4k |
All Works
Login with ORCID to disown or claim papers
Loading papers...